Associations - CTLA4 inhibitor

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials J Immunother Cancer - 3 days (New C3) KN046 Sensitive : C3 J Immunother Cancer - 3d	KN046 Sensitive: C3 – Early Trials J Immunother Cancer - 3 days KN046 Sensitive : C3 J Immunother Cancer - 3 days - (New C3)
ICOS overexpression	Melanoma	ICOS overexpression	Melanoma	PD1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials Biomark Res - 4 days (New C3) PD1 inhibitor + CTLA4 inhibitor Sensitive : C3 Biomark Res - 4d	PD1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials Biomark Res - 4 days PD1 inhibitor + CTLA4 inhibitor Sensitive : C3 Biomark Res - 4 days - (New C3)
ICOS Methylation	Melanoma	ICOS Methylation	Melanoma	PD1 inhibitor + CTLA4 inhibitor Resistant: C3 – Early Trials Biomark Res - 4 days (New C3) PD1 inhibitor + CTLA4 inhibitor Resistant : C3 Biomark Res - 4d	PD1 inhibitor + CTLA4 inhibitor Resistant: C3 – Early Trials Biomark Res - 4 days PD1 inhibitor + CTLA4 inhibitor Resistant : C3 Biomark Res - 4 days - (New C3)
IL6 elevation	Melanoma	IL6 elevation	Melanoma	nivolumab + ipilimumab Resistant: B - Late Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Resistant : B ASCO 2023 - 1wk	nivolumab + ipilimumab Resistant: B - Late Trials ASCO 2023 - 1 week nivolumab + ipilimumab Resistant : B ASCO 2023 - 1 week - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : A1 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: A1 - Approval ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : A1 ASCO 2023 - 1 week - (New C3)
BRAF mutation	Melanoma	BRAF mutation	Melanoma	nivolumab + ipilimumab Sensitive: B - Late Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : B ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: B - Late Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : B ASCO 2023 - 1 week - (New C3)
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	KN046 + KN026 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) KN046 + KN026 Sensitive : C2 ASCO 2023 - 1wk	KN046 + KN026 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week KN046 + KN026 Sensitive : C2 ASCO 2023 - 1 week - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	cadonilimab + AK117 Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) cadonilimab + AK117 Sensitive : C3 ASCO 2023 - 1wk	cadonilimab + AK117 Sensitive: C3 – Early Trials ASCO 2023 - 1 week cadonilimab + AK117 Sensitive : C3 ASCO 2023 - 1 week - (New C3)
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	cadonilimab + AK117 Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) cadonilimab + AK117 Sensitive : C3 ASCO 2023 - 1wk	cadonilimab + AK117 Sensitive: C3 – Early Trials ASCO 2023 - 1 week cadonilimab + AK117 Sensitive : C3 ASCO 2023 - 1 week - (New C3)
PMS2 mutation + MLH1 mutation	Gastric Cancer	PMS2 mutation + MLH1 mutation	Gastric Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
PMS2 mutation + MLH1 mutation	Colorectal Cancer	PMS2 mutation + MLH1 mutation	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
MSH2 deletion + MSH6 deletion	Rectal Cancer	MSH2 deletion + MSH6 deletion	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
MLH1 deletion+ PMS2 deletion	Rectal Cancer	MLH1 deletion+ PMS2 deletion	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
MSH2 mutation	Rectal Cancer	MSH2 mutation	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
MSH6 mutation	Rectal Cancer	MSH6 mutation	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week nivolumab + ipilimumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
KDM1A expression	Small Cell Lung Cancer	KDM1A expression	Small Cell Lung Cancer	nivolumab + ipilimumab Resistant: C3 – Early Trials J Thorac Oncol - 2 weeks (New C3) nivolumab + ipilimumab Resistant : C3 J Thorac Oncol - 2wk	nivolumab + ipilimumab Resistant: C3 – Early Trials J Thorac Oncol - 2 weeks nivolumab + ipilimumab Resistant : C3 J Thorac Oncol - 2 weeks - (New C3)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials N Engl J Med - 3 weeks (New B) nivolumab + ipilimumab + cabozantinib tablet Sensitive : B N Engl J Med - 3wk	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials N Engl J Med - 3 weeks nivolumab + ipilimumab + cabozantinib tablet Sensitive : B N Engl J Med - 3 weeks - (New B)
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
LDH elevation	Melanoma	LDH elevation	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1
BRAF V600 wild-type	Melanoma	BRAF V600 wild-type	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	cadonilimab Sensitive: A1 - Approval cadonilimab Sensitive : A1	cadonilimab Sensitive: A1 - Approval cadonilimab Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer	EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	ipilimumab Sensitive: A2 - Guideline ipilimumab Sensitive : A2	ipilimumab Sensitive: A2 - Guideline ipilimumab Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
TMB-H	Melanoma	TMB-H	Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
TMB-H	Solid Tumor	TMB-H	Solid Tumor	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
PD-L1 underexpression	Lung Adenocarcinoma	PD-L1 underexpression	Lung Adenocarcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2

CTLA4 inhibitor

CTLA4 inhibitor

Associations(340)

Associations
(340)